Strong export demand and international product

This preview shows page 30 - 32 out of 48 pages.

Strong export demand and international product registration have led BPL to embark on a massive capacity expansion program, as evident in completion of the FDA standard plant will help it to enter into the USA and EUROPE markets. Beximco Pharmaceuticals Ltd manufactures GLAXOSMITHKLINE in halation aerosol ‘ Ventolin’ which proves the quality of the company’s world-class machinery. Beximco Pharma has already established its value in the customer’s eye as a reputed company who supplies quality product’s in the market. So the company can enter into the existing market with its new innovation products without fear. Beximco Pharma strategic strengths include strong recognition of its brands, highly skilled work force and diversified business mix. Beximco Pharmaceuticals Ltd. has products of different therapeutic classes, each of which, occupies a prominent position in the market and the heart of our customers and shareholders. Weaknesses:- Beximco Pharmaceuticals Ltd (BPL) has a narrower product line and number of products than its most important challenger in the market. Beximco Pharmaceuticals Ltd (BPL) produces very small kind of inject tables comparing to its competitors. The injects tables market is a large one and it is captured by the rival companies. BPL’s sales activities are less founded in remote rural areas.
Opportunity:- Beximco Pharmaceuticals Limited is the leading drug manufacturer in Bangladesh, announces that it has commenced exporting drugs into Belize of Central America. Beximco Pharmaceuticals Ltd. manufacturer and the largest pharmaceutical exporter of Bangladesh, has started supplying medicines to PacificIsland country, Fiji, a company statement said today. BPL included twenty five products covering a wide range of therapeutic categories, including antihistamine, antihypertensive, antibacterial, lipid lowering, respiratory, antiulcerant and pain relievers. The Company already exports pharmaceuticals into a number of countries in East Africa and South East Asia and is now seeking to build its presence in Central and South America. Threads Beximco Pharmaceuticals Limited (BPL) has launched a novel, new generation corticosteroid inhaler Cesonide for the treatment of adults suffering from persistent asthma. Beximco Pharma has a strong commitment to developing the next generation of anti-inflammatory agents for the treatment of asthma. Leading drug manufacturer in Bangladesh Beximco Pharmaceuticals Limited introduced Oseflu capsule for the prevention and treatment of human cases of Avian influenza (H5N1) causing Bird flu. Due to its safety and effectiveness against pandemic strains of influenza, the World Health Organization has recommended it in the event of an influenza pandemic. Competition from the local Pharmaceuticals companies and the very specifically in context of price is a major threat for BPL.

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture